US/UK/Canada

Share

Links

Quotes

This order is of strategic importance for Attana, since we are now involved at an early stage in designing R&D projects for a major drug development project. The order shows a market acceptance for our technology and capability to characterize interactions with cells, tissues, viruses etc it also provides a value of our application knowledge and the advises we can provide.
International Sales Manager Thomas Ljungberg
Pick a time period -
Tags ( Active)

The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.

The Swedish Knowledge-Foundation has granted SEK 12 million to the project "Advanced materials for individualized medicine and diagnostics ". The project is coordinated by Prof. Ian Nicholls at Linnaeus University  in collaboration with Attana AB, AroCell AB, Capitainer AB, Luma Metall AB and Region Kalmar.The aim of the project is to provide precise information about the medical conditions of

New publication – Attana’s technology employed in the development of antibacterial coatings for future surgical implants

A new paper has been published in MicrobiologyOpen  by Prof. Hedhammar and co-workers at the Royal Institute of Technology and Stockholm University. In this paper, recombinant spider silk was functionalized with enzymes having antibacterial properties. This has the potential to be used as surface coatings of surgical implants and other medical equipment to avoid bacterial colonization. Attana’s QCM technology was employed to evaluate the immobilization of the enzymes to the spider silk and the assembly of the spider silk.Bacteria

Attana participates at the 11th Drug Discovery Innovation Programme, DDIP 2020, Munich April 23-24, 2020

The DDIP-conference focus on new technologies for improved drug development. At the conference leading professionals within industry and academy will participate. Attana will give a presentation at the scientific session and have an exhibition booth.Attana´s CEO Teodor Aastrup will give a presentation with focus on success cases where Attana’s 3[rd] generation biosensor has increased the efficiency in drug development. To learn more about the conference and the participants please read here. 

Attana participates at the First Congress of Clinical Biochemists and Laboratory Specialists of Serbia conference, KKBLM, Belgrade, November 27-29, 2019

The KKBLM-conference is intended for professionals in clinical biochemistry and laboratory medicine with a focus on the development of new laboratory tools and technology for medical diagnostics. The conference will be attended by leading specialists within industry and academia.Attana will participate in the discussions and scientific sessions together with HVD Life Sciences and present at an exhibition booth. The focus will be to present how Attana’s 3rd generation biosensor is used in laboratory medicine and clinical biochemistry, biomarker screening and how it can increase the

Attana participates at the Drug Discovery Innovation Programme, DDIP 2019, Barcelona November 28-29, 2019

The DDIP-conference focus on new technologies for improved drug development. At the conference leading professionals within industry and academy will participate. Attana will give a presentation at the scientific session and have an exhibition booth.Attana’s CEO Teodor Aastrup will give the presentation “In vivo Predictions by Attana”. Focus will be on how Attana’s 3[rd] generation biosensor has increased the efficiency in drug development. To learn more about the conference and the participants please read here. 

New Attana publication - Increased target specificity for new drugs by applying Attana´s technology to understand and optimize multivalent drug interactions

Attana’s technology was extensively used in a new paper published in Biosensors and Bioelectronics. The paper is a result of a collaboration project, which originates from the EU-project Dynano , between University of Namur, KTH - Royal Institute of Technology, University of Massachusetts Lowell, Linnaeus University and Attana. In the paper it is demonstrated that the Attana technology is an excellent tool to characterize and distinguish between different kinds of interactions, which are important for the development of new drugs with improved specificity.In the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe